Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain,” covering its machine learning–based platform for analyzing magnetic resonance spectroscopy (MRS) data. The patent strengthens the company’s ability to scale by protecting the use of artificial intelligence (AI) in future versions of its Nociscan platform, which converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine.
Chronic low back pain affects approximately 266 million people worldwide, representing a significant global healthcare challenge. Aclarion’s cloud-based Nociscan platform addresses this by using proprietary signal processing and AI algorithms to identify biomarkers associated with disc pain. The newly issued patent covers machine learning models that extract quantitative biomarkers from MRS data to generate standardized classifications for pain-related conditions. It also includes AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability is expected to enable consistent, reproducible outputs across different imaging systems and clinical sites, marking a key step toward broader clinical adoption.
Brent Ness, Chief Executive Officer of Aclarion, stated, “This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice. By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent expands Aclarion’s intellectual property portfolio to 64 issued and pending patents worldwide, reinforcing its long-term competitive moat. The company’s strategy focuses on building a differentiated, software-driven platform in the large and underserved chronic low back pain market. Clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. To read the full patent, click here.
For more news from Aclarion, visit their Latest News page. To find a Nociscan center, view the site map here.
